ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0735

Paediatric Sarcoidosis: Phenotype of a Retrospective Cohort of Biopsy-proven Patients

Kerstin Nott1, Veronica Nott2 and Sandrine Compeyrot-Lacassagne1, 1Great Ormond Street Hospital for Children, London, United Kingdom, 2Imperial College, ANDOVER, United Kingdom

Meeting: ACR Convergence 2020

Keywords: Cohort Study, Pediatric rheumatology

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 7, 2020

Title: Pediatric Rheumatology – Clinical Poster II: JIA

Session Type: Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Paediatric sarcoidosis is a multisystemic inflammatory condition characterised by the formation of non-caseating granulomata that may lead to end-organ damage. Diagnosis is challenging as a compatible clinical-radiographic presentation with histopathologic confirmation is needed. Caution must be exercised to exclude granulomata of infectious aetiology as well as those seen in immunodeficiencies associated with immune dysregulation. Little is known about this rare disease’s presentation and outcome in children. We report a retrospective cohort of children with biopsy-confirmed sarcoidosis, their treatment and the course of the disease.

Methods: Patients’ notes were reviewed retrospectively, and multisystem involvement identified. We included patients with biopsies, performed or reviewed at our centre between 2010 and 2020, which were consistent with sarcoidosis and a compatible clinical phenotype.

Results: We identified 42 children with biopsy-proven sarcoidosis. Mean age at diagnosis was 9.4 years; male to female ratio 0.68. Twenty-seven of 42 patients were of Afro-Caribbean descent. Tissues biopsied included lymph node, skin, kidney, liver, lung, submandibular, lacrimal and salivary gland, eye, spleen, bone, brain and synovium.

28 patients had lymphadenopathy, 16 glandular involvement, 17 liver, 17 pancreas, 13 renal, 11 spleen, 27 skin, 14 lung involvement, 11 arthritis, 4 tenosynovitis, 3 hearing loss, 2 bone, 1 cerebral, and 25 eye involvement.

Remarkable laboratory findings included raised levels of serum calcium in 9, amylase in 16, lipase in 4 and ACE in 30 patients; 12 patients had abnormal renal function, 13 abnormal liver function; 13 patients were tested for NOD2 mutations, which were present in 5.

38 patients received treatment for sarcoidosis. Of those, 37 received steroids, 16 intravenous followed by oral steroids, 18 oral steroids only and 18 received steroid eye drops; 36 patients received disease-modifying antirheumatic drugs (DMARDs) including 26 methotrexate, 11 mycophenolate mofetil and 10 azathioprine; 4 patients received hydroxychloroquine, 5 cyclophosphamide; 10 received biologic therapy including anti-TNF, interleukin-1 and IL-6 blockade, JAK inhibitor and rituximab.

All patients had a good response to steroids, and most responded to methotrexate. The treatment of a subset of patients was escalated to include a biologic agent, owing to grumbling disease activity. Although most of the patients were able to wean off regular steroids, the majority remained on long-term DMARDs to maintain disease control.

Conclusion: Our study suggests that non-caseating granulomatous inflammation on biopsy, multiorgan involvement, response to steroids and chronic course are hallmarks of paediatric sarcoidosis. DMARDs, in particular methotrexate, were used with efficacy. When response was partial, addition of a biologic agent was beneficial, particularly in ocular disease. Additional organ involvement occurs over time when the disease is not fully controlled. However, no biomarkers are available to assess disease activity apart from ACE, which demonstrated low sensitivity. Prospective cohort studies are needed to define this rare paediatric disease.


Disclosure: K. Nott, None; V. Nott, None; S. Compeyrot-Lacassagne, None.

To cite this abstract in AMA style:

Nott K, Nott V, Compeyrot-Lacassagne S. Paediatric Sarcoidosis: Phenotype of a Retrospective Cohort of Biopsy-proven Patients [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/paediatric-sarcoidosis-phenotype-of-a-retrospective-cohort-of-biopsy-proven-patients/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/paediatric-sarcoidosis-phenotype-of-a-retrospective-cohort-of-biopsy-proven-patients/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology